Two high‑profile listings targeted Hong Kong capital markets as companies pushed to fund R&D and international expansion. Insilico Medicine closed a Hong Kong IPO, delivering proceeds to accelerate its AI‑driven drug discovery platform and pipeline. Shenzhen Edge Medical filed for a HKEX listing to raise roughly US$154 million to advance its surgical robotics systems and expand outside China. The deals reflect renewed public‑markets appetite for capital‑intensive med‑tech and AI‑enabled biotech platforms and will test investor tolerance for long‑horizon product commercialization.